NITRO-DUR 0.2 PATCH (EXTENDED RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

NITROGLYCERIN

متاح من:

USPHARMA LTD

ATC رمز:

C01DA02

INN (الاسم الدولي):

GLYCERYL TRINITRATE

جرعة:

0.2MG

الشكل الصيدلاني:

PATCH (EXTENDED RELEASE)

تركيب:

NITROGLYCERIN 0.2MG

طريقة التعاطي:

TRANSDERMAL

الوحدات في الحزمة:

30X10CM SQ

نوع الوصفة الطبية :

Ethical

المجال العلاجي:

NITRATES AND NITRITES

ملخص المنتج:

Active ingredient group (AIG) number: 0103615026; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2011-02-11

خصائص المنتج

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
NITRO-DUR
®
0.2
NITRO-DUR
®
0.4
NITRO-DUR
®
0.6
NITRO-DUR
®
0.8
Nitroglycerin Transdermal Sy
stem
NITRO-DUR 0.2 (Rated release in vivo 0.2 mg/hour, 10 cm
2
)
NITRO-DUR 0.4 (Rated release in vivo 0.4 mg/hour, 20 cm
2
)
NITRO-DUR 0.6 (Rated release in vivo 0.6 mg/hour, 30 cm
2
)
NITRO-DUR 0.8 (Rated release in vivo 0.8 mg/hour, 40 cm
2
)
Antianginal A
gent
DIN Owner:
USPHARMA LTD.
13900 NW 57th Court
Miami Lakes, FL 33014, USA
Imported by:
DR. REDDY'S LABORATORIES
CANADA INC.
5580 Explorer Drive, Suite 204,
Mississauga, ON L4W 4Y1
CANADA
Date of Revision:
March 26, 2019
Submission Control No: 223266
_NITRO-DUR (Nitroglycerin Transdermal System) _
_Page 1 of 27_
_NITRO-DUR (Nitroglycerin Transdermal System)_
_Page 2 _
_of26_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG
INTERACTIONS
....................................................................................................7
DOSAGE AND
ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STAB
IL
I
T
Y
............................................................................................9
SPECI